Evidence map›Paper›PMID 26686045›Full record

ArticleThe Lancet. Haematology2015

Glucose-6-phosphate dehydrogenase deficiency and the risk of malaria and other diseases in children in Kenya: a case-control and a cohort study.

Sophie Uyoga, Carolyne M Ndila, Alex W Macharia, Gideon Nyutu, Shivang Shah, Norbert Peshu, Geraldine M Clarke, Dominic P Kwiatkowski, Kirk A Rockett, Thomas N Williams and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Lancet. Haematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 3 pooled it
13.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Human genetic variations conferring resistance to malaria.Journal of translational medicine · 2025
    Review
  13. Review
  14. Article
  15. Article
  16. Revealing the secrets of Blue Zones.Frontiers in pharmacology · 2024
    Review
  17. Pathogens (Basel, Switzerland) · 2023
    Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Sophie UyogaDepartment of Epidemiology and Demography, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Carolyne M NdilaDepartment of Epidemiology and Demography, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Alex W MachariaDepartment of Epidemiology and Demography, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Gideon NyutuDepartment of Epidemiology and Demography, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Shivang ShahWellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Norbert PeshuDepartment of Epidemiology and Demography, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Geraldine M ClarkeWellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Dominic P KwiatkowskiWellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK; Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Kirk A RockettWellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Thomas N WilliamsDepartment of Epidemiology and Demography, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; Department of Medicine, Imperial College, St Mary's Hospital, London, UK. Electronic address: tom.williams@imperial.ac.uk.
MalariaGEN Consortium
Kenya Medical Research Institute · KECentre for Human Genetics · GBNational Institute of Allergy and Infectious Diseases · USUniversity of Oxford · GB

Funding

Medical Research Council G0600718Medical Research Council G19/9Medical Research Council MC_UP_A900_1118Medical Research Council MR/M006212/1Wellcome Trust 077383Wellcome Trust 084535Wellcome Trust 090532Wellcome Trust 090770Wellcome Trust 091758Wellcome Trust 092654
6 · The paper itself

Abstract

backgroundThe global prevalence of X-linked glucose-6-phosphate dehydrogenase (G6PD) deficiency is thought to be a result of selection by malaria, but epidemiological studies have yielded confusing results. We investigated the relationships between G6PD deficiency and both malaria and non-malarial illnesses among children in Kenya.

methodsWe did this study in Kilifi County, Kenya, where the G6PD c.202T allele is the only significant cause of G6PD deficiency. We tested the associations between G6PD deficiency and severe and complicated Plasmodium falciparum malaria through a case-control study of 2220 case and 3940 control children. Cases were children aged younger than 14 years, who visited the high dependency ward of Kilifi County Hospital with severe malaria between March 1, 1998, and Feb 28, 2010. Controls were children aged between 3-12 months who were born within the same study area between August 2006, and September 2010. We assessed the association between G6PD deficiency and both uncomplicated malaria and other common diseases of childhood in a cohort study of 752 children aged younger than 10 years. Participants of this study were recruited from a representative sample of households within the Ngerenya and Chonyi areas of Kilifi County between Aug 1, 1998, and July 31, 2001. The primary outcome measure for the case-control study was the odds ratio for hospital admission with severe malaria (computed by logistic regression) while for the cohort study it was the incidence rate ratio for uncomplicated malaria and non-malaria illnesses (computed by Poisson regression), by G6PD deficiency category.

findings2863 (73%) children in the control group versus 1643 (74%) in the case group had the G6PD normal genotype, 639 (16%) versus 306 (14%) were girls heterozygous for G6PD c.202T, and 438 (11%) versus 271 (12%) children were either homozygous girls or hemizygous boys. Compared with boys and girls without G6PD deficiency, we found significant protection from severe malaria (odds ratio [OR] 0·82, 95% CI 0·70-0·97; p=0·020) among G6PD c.202T heterozygous girls but no evidence for protection among G6PD c.202T hemizygous boys and homozygous girls (OR 1·18, 0·99-1·40; p=0·056). Median follow-up for the mild disease cohort study was 2·24 years (IQR 2·22-2·85). G6PD c.202T had no effect on other common diseases of childhood in heterozygous girls (incidence rate ratio 0·98, 95% CI 0·86-1·11; p=0·82) or homozygous girls or hemizygous boys (0·93, 0·82-1·04; p=0·25), with the sole exception of a marginally significant increase in the incidence of helminth infections among heterozygous girls.

interpretationHeterozygous girls might be the driving force for the positive selection of G6PD deficiency alleles. Further studies are needed to definitively establish the mechanisms by which G6PD deficiency confers an advantage against malaria in heterozygous individuals. Such studies could lead to the development of new treatments.

fundingWellcome Trust, UK Medical Research Council, European Union, and Foundation for the National Institutes of Health (as part of the Bill & Melinda Gates Grand Challenges in Global Health Initiative).

Indexed as

AdolescentCase-Control StudiesChildChild, PreschoolCohort StudiesFemaleGlucosephosphate Dehydrogenase DeficiencyHeterozygoteHumansInfantKenyaMalariaMaleRisk FactorsUnited States

Identifiers

PMID26686045
PMCPMC4703047
OpenAlexW1869517112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.